Sarizotan Designated Orphan Drug for Neurologic Disorder
Newron Pharmaceuticals announced that the Food and Drug Administration (FDA) has granted Orphan Drug designation to sarizotan for the treatment of Rett syndrome.
Sarizotan is a 5HT1A agonist and D2 agonist/antagonist. During preclinical testing, sarizotan has shown a 70–85% reduction in apneas and hyperventilation episodes with both acute and chronic dosing.
Newron also recently announced that the FDA had accepted for filing the New Drug Application (NDA) for Xadago (safinamide) as add-on therapy in both early and mid-to-late stage Parkinson's disease (PD) patients who are inadequately managed on their current treatment.
For more information visit Newron.com.